READ BEFORE ENTERING; This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.
syringe

The Good News About the MMR Vaccine!

This page discusses some critical things you should know about the MMR vaccine. Here is the good news: According to the package insert, the risk of serious neurological disorders following live measles virus vaccine administration remains less than the risk of encephalitis.

In women, incidence rates for arthritis and arthralgia are 12%-26% and can last for years. Yes, they have admitted vaccines cause autoimmune diseases. and more good news, in women older than 35, these reactions are generally well tolerated and rarely interfere with normal activities. (that is on the package insert)

doctor cartoon vaccine, medicine, health care

WARNINGS:

FROM THE PACKAGE INSERT

Due caution should be employed in the administration of M-M-R II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided. The physician should be alert to the temperature elevation which may occur following vaccination.

However, an approximately 2-fold increase in the risk of seizure or febrile seizure during 7-10 days or 5-12 days after MMRV vaccination was found among children aged 10-24 months, although the highest incidence of seizure was still lower than 2.95‰.

CONCLUSIONS:

The first MMRV vaccine dose in children aged 10-24 months was associated with an elevated risk of seizure or febrile seizure.

FROM THE PACKAGE INSERT

Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R II (or its component vaccines) may develop thrombocytopenia with repeat doses. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases (see ADVERSE REACTIONS)

Thrombocytopenia:

Thrombocytopenia is when you don’t have enough platelets in your blood. Platelets help your blood clot, which stops bleeding.In the severe form, you can suddenly bleed in your eyes, gums, or bladder. We usually have a platelet count of 150,000 to 400,000. When you acquire thrombocytopenia after vaccination, your number falls under 150,000.

WebMD will tell you they do not know what causes it:

Thrombocytopenia has many causes. One of the most common reasons of low platelets is a condition called immune thrombocytopenia (ITP). You may hear it called by its old name, idiopathic thrombocytopenic purpura. Although doctors don’t know what causes ITP, they see that it happens when your immune system — your body’s primary defense against disease — doesn’t work right. Your antibodies, which are supposed to attack infections, instead mistakenly destroy your platelets.

FROM THE PACKAGE INSERT

Measles inclusion body encephalitis{44} (MIBE), pneumonitis{45}, and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with the measles-containing vaccine.  Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient, is demonstrated.

FROM THE PACKAGE INSERT

Carcinogenesis, Mutagenesis, Impairment of Fertility
M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility

Do vaccines cause cancer? No one knows. They have never tested it and don’t plan to.

Does this make you suspicious? Why then have they not tested this out and found the science behind this?   Let’s do a hypothetical for a moment. Why do you think they refuse to test it to see if it causes cancer?

1. They did testing and found that it does cause cancer, so they now refuse to release the results,

2. The vaccine makers examine vaccines for adverse side effects and will not disclose this, or they would be out of business.

3. Some vaccines are grown on cancerous tissue, which is a fact, but they are afraid to test it and find the results.

4. The Physicians’ Desk Reference (PDR) states that in addition to mercury, aluminum, and formaldehyde, vaccines may also contain SV40, bovine serums, latex, neomycin, and other known carcinogens.

Simian Virus 40 in Human Cancers.

CONCLUSION: These results establish that SV40 is associated significantly with brain tumors, bone cancers, malignant mesothelioma, and non-Hodgkin’s lymphoma. Studies are needed to assess the current prevalence of SV40 infections.

A Closer Look at Bovine Serums – From the FDA Website:

On April 19, 2000, CBER issued a letter reminding manufacturers that the USDA list of BSE-countries had been expanded to include not only those countries where BSE was known to exist but also those where BSE may exist (FR, January 6, 1998).

CBER strongly recommended “that manufacturers take whatever steps are necessary to assure that materials derived from all species of ruminant animals born, raised or slaughtered in countries where BSE is known to exist, or countries where the USDA has been unable to assure FDA that BSE does not exist, are not used in the manufacture of FDA-regulated products intended for administration to humans.”

Although Canada and the US have each reported one case of BSE and the USDA has placed Canada on the list of countries with BSE, FDA has not recommended that manufacturers find a new source for bovine-derived materials obtained from these countries for use in the manufacture of drugs or biological products. The FDA believes that the control measures in place assure the safety of bovine-derived materials sourced from these countries and used in the manufacture of vaccines.

Are bovine-derived materials from North America used in the manufacture of vaccines?

Yes, bovine-derived materials from North America, specifically the US and Canada, are used in vaccine manufacture. Since there has been an extensive movement of live cows and cow-derived materials between Canada and the US, it is difficult to establish that an animal has not been born, raised, or slaughtered in Canada. Moreover, control measures, such as the ruminant-to-ruminant feed ban, have been similar in the two countries. Therefore, FDA has not recommended that manufacturers using bovine-derived material from Canada replace those materials with materials from countries not on the USDA list of countries that have BSE or are at risk of BSE.

FROM THE PACKAGE INSERT

Local health authorities may recommend measles vaccination of infants between 6 to 12 months of age in outbreak situations. This population may fail to respond to the components of the vaccine. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established.

The younger the infant, the lower the likelihood of seroconversion (see CLINICAL PHARMACOLOGY). Such infants should receive a second dose of M-M-R II between 12 to 15 months of age followed by revaccination at elementary school entry.{32} Unnecessary doses of a vaccine are best avoided by ensuring that written documentation of vaccination is preserved and a copy given to each vaccinee’s parent or guardian.

This one speaks for itself. They will recommend something for your new delicate infant that has not been tested for safety and it most likely won’t work, but you should take the risk. Who benefits from this?

FROM THE PACKAGE INSERT

Nervous System

Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia. Encephalitis and encephalopathy have been reported approximately once for every 3 million doses of M-M-R II or measles-, mumps-, and rubella-containing vaccine administered since licensure of these vaccines. The risk of serious neurological disorders following live measles virus vaccine administration remains less than the risk of encephalitis and encephalopathy following infection with wild-type measles (1 per 1000 reported cases)

GOOD NEWS!

The risk of severe life-altering neurological disorders following live measles virus vaccine administration is less than the risk of encephalitis and encephalopathy following infection with wild-type measles (1 per 1000 reported cases). So what are the odds that they get the virus in the first place? Factor that in.

To date, they have paid out over 4.3 billion dollars to those who suffered vaccine injuries.

Most don’t qualify for a lawsuit since the guidelines are so rigorous, but you will if you report severe neurological damage in time. Only an estimated 1-10% of injuries are reported.

ADVERSE REACTIONS
The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:

Body as a Whole
Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.
Cardiovascular System
Vasculitis.

Digestive System
Pancreatitis; diarrhea; vomiting; parotitis; nausea.
Endocrine System
Diabetes mellitus.
Hemic and Lymphatic System
Thrombocytopenia (see WARNINGS, Thrombocytopenia); purpura; regional lymphadenopathy;
leukocytosis.
Immune System
Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as
angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or
without an allergic history.

Musculoskeletal System
Arthritis; arthralgia; myalgia.
Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection
with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females
and least in prepubertal children. This type of involvement as well as myalgia and paresthesia, have also
been reported following administration of MERUVAX II.
Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent
virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed
chronic joint symptoms.
Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In
women, incidence rates for arthritis and arthralgia are generally higher than those seen in children
(children: 0-3%; women: 12-26%),{17,56,57} and the reactions tend to be more marked and of longer
duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls,
the reactions appear to be intermediate in incidence between those seen in children and in adult women.
Even in women older than 35 years, these reactions are generally well tolerated and rarely interfere with
normal activities.

Nervous System
Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see
CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS);
acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile
convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia.
Encephalitis and encephalopathy have been reported approximately once for every 3 million doses of
M-M-R II or measles-, mumps-, and rubella-containing vaccine administered since licensure of these
vaccines.
The risk of serious neurological disorders following live measles virus vaccine administration remains
less than the risk of encephalitis and encephalopathy following infection with wild-type measles (1 per
1000 reported cases).{58,59}
In severely immunocompromised individuals who have been inadvertently vaccinated with measlescontaining vaccine; measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct
consequence of disseminated measles vaccine virus infection have been reported (see
CONTRAINDICATIONS). In this population, disseminated mumps and rubella vaccine virus infection have
also been reported.

There have been reports of subacute sclerosing panencephalitis (SSPE) in children who did not have a
history of infection with wild-type measles but did receive measles vaccine. Some of these cases may
have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination.
Based on estimated nationwide measles vaccine distribution, the association of SSPE cases to measles
vaccination is about one case per million vaccine doses distributed. This is far less than the association
with infection with wild-type measles, 6-22 cases of SSPE per million cases of measles. The results of a
retrospective case-controlled study conducted by the Centers for Disease Control and Prevention suggest
that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its
inherent higher risk of SSPE.{60}
Cases of aseptic meningitis have been reported to VAERS following measles, mumps, and rubella
vaccination. Although a causal relationship between the Urabe strain of mumps vaccine and aseptic
meningitis has been shown, there is no evidence to link Jeryl Lynn™ mumps vaccine to aseptic
meningitis.

Respiratory System
Pneumonia; pneumonitis (see CONTRAINDICATIONS); sore throat; cough; rhinitis.
Skin
Stevens-Johnson syndrome; erythema multiforme; urticaria; rash; measles-like rash; pruritis.
Local reactions including burning/stinging at injection site; wheal and flare; redness (erythema);
swelling; induration; tenderness; vesiculation at injection site; Henoch-Schönlein purpura; acute
hemorrhagic edema of infancy.
Special Senses — Ear
Nerve deafness; otitis media.
Special Senses — Eye
Retinitis; optic neuritis; papillitis; retrobulbar neuritis; conjunctivitis.
8
Urogenital System
Epididymitis; orchitis.
Other
Death from various, and in some cases unknown, causes has been reported rarely following
vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been
established in healthy individuals (see CONTRAINDICATIONS). No deaths or permanent sequelae were
reported in a published post-marketing surveillance study in Finland involving 1.5 million children and
adults who were vaccinated with M-M-R II during 1982 to 1993.{61}
Under the National Childhood Vaccine Injury Act of 1986, health-care providers and manufacturers are
required to record and report certain suspected adverse events occurring within specific time periods after
vaccination. However, the U.S. Department of Health and Human Services (DHHS) has established a
Vaccine Adverse Event Reporting System (VAERS) which will accept all reports of suspected events.{49}
A VAERS report form as well as information regarding reporting requirements can be obtained by calling
VAERS 1-800-822-7967.

This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.